October 20, 2022 07:00 AM EDT

Bristol Myers spells out Opdivo win in melanoma — how does it stack up against Keytruda?

Amber Tong

Bristol Myers Squibb is ready for a data showdown with Merck as they move their respective PD-1 inhibitors into earlier lines of melanoma treatment. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Bristol Myers spells out Opdivo win in melanoma — how does it stack up against Keytruda?

Amber Tong

Sign up to read this article for free.

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks

Updated: Amgen obesity shot shows 20% weight loss, but dosing questions hang over readout

Updated: Roche buys out CAR-T partner Poseida for $1B upfront

Food allergy biotech Alladapt closes after Phase 3 talks with FDA

Alector says Alzheimer's program targeting microglia fails Phase 2, stock dives

Soleno’s rare pediatric disease drug faces PDUFA delay by three months

Bris­tol My­ers spells out Op­di­vo win in melanoma — how does it stack up against Keytru­da?

Amber Tong

Sign up to read this article for free.

more like this

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Food al­ler­gy biotech Al­ladapt clos­es af­ter Phase 3 talks with FDA

Alec­tor says Alzheimer's pro­gram tar­get­ing mi­croglia fails Phase 2, stock dives

Soleno’s rare pe­di­atric dis­ease drug faces PDU­FA de­lay by three months

Bristol Myers spells out Opdivo win in melanoma — how does it stack up against Keytruda?

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks

Updated: Amgen obesity shot shows 20% weight loss, but dosing questions hang over readout

Updated: Roche buys out CAR-T partner Poseida for $1B upfront

Food allergy biotech Alladapt closes after Phase 3 talks with FDA

Alector says Alzheimer's program targeting microglia fails Phase 2, stock dives

Soleno’s rare pediatric disease drug faces PDUFA delay by three months